(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $26.76
Išleistas: 14 vas. 2024 @ 19:06
Grąža: -48.84%
Ankstesnis signalas: vas. 14 - 16:30
Ankstesnis signalas:
Grąža: 6.23 %
Live Chart Being Loaded With Signals
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults...
Stats | |
---|---|
Šios dienos apimtis | 1.46M |
Vidutinė apimtis | 1.05M |
Rinkos kapitalizacija | 823.89M |
EPS | $0 ( 2024-04-25 ) |
Kita pelno data | ( $-1.590 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.630 |
ATR14 | $0.0200 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Greene Barry E | Buy | 168 000 | Stock Option (Right to Buy) |
2024-02-13 | Cook Anne Marie | Buy | 11 250 | Common Stock |
2024-02-13 | Cook Anne Marie | Buy | 22 500 | Stock Option (Right to Buy) |
2024-02-13 | Gault Laura | Buy | 22 500 | Stock Option (Right to Buy) |
2024-02-13 | Gault Laura | Buy | 11 250 | Common Stock |
INSIDER POWER |
---|
92.68 |
Last 97 transactions |
Buy: 1 228 960 | Sell: 86 892 |
Tūris Koreliacija
SAGE Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
RGLD | 0.868 |
ISEM | 0.866 |
GTH | 0.86 |
SOCL | 0.859 |
MATW | 0.857 |
SGII | 0.856 |
HCM | 0.854 |
IIIV | 0.854 |
MCHI | 0.853 |
GAME | 0.852 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
LLNW | -0.876 |
AMGN | -0.859 |
EA | -0.841 |
LAWS | -0.835 |
AHPI | -0.812 |
ASPS | -0.812 |
AUID | -0.811 |
CNET | -0.806 |
ODT | -0.804 |
HCAQ | -0.801 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
SAGE Therapeutics Inc Koreliacija - Valiuta/Žaliavos
SAGE Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $86.46M |
Bruto pelnas: | $84.30M (97.50 %) |
EPS: | $-9.05 |
FY | 2023 |
Pajamos: | $86.46M |
Bruto pelnas: | $84.30M (97.50 %) |
EPS: | $-9.05 |
FY | 2022 |
Pajamos: | $7.69M |
Bruto pelnas: | $6.87M (89.42 %) |
EPS: | $-8.49 |
FY | 2021 |
Pajamos: | $6.31M |
Bruto pelnas: | $5.76M (91.23 %) |
EPS: | $-7.80 |
Financial Reports:
No articles found.
SAGE Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.